Sun Lays Out Halol Compliance Plan As Results Trounce Forecasts
This article was originally published in PharmAsia News
Executive Summary
India’s Sun Pharma has surprised investors with a strong leap in profit and it says it will lodge a request by the end of June with the US FDA to re-inspect its troubled Halol plant, in the first official indication of a likely timeline for the restoration of compliance at the facility.
You may also be interested in...
Analysts Cut Sun Forecasts After New Halol Site Faults
Analysts are cutting back profit forecasts for Indian generic giant Sun Pharma after the US FDA detailed a host of new testing and quality control issues at the company’s key Halol factory.
Share Fillip As Indian Pharma Crests US Regulatory Hump
For the last few years, Indian generic companies have been making headlines for all the wrong reasons, rapped by the US Food and Drug Administration over problems ranging from fudged test results to poor-quality manufacturing standards. But lately, the firms have been enjoying a run of good regulatory tidings, giving a fillip to their share prices.
Biocon, Quark Win Pioneering Indian Nod For RNAi Eye Therapy Trial
Asia’s biggest biotech company, India’s Biocon Ltd, has announced it will conduct what it says is the first-ever clinical trial of a siRNA therapy in India with US partner Quark, is aimed at tackling a rare eye condition.